administering FDA regulations pertaining to the manufacturing/ processing, packing, or holding of food for consumption in the United States.

The Produce Regulatory Program Standards (PRPS) are the result of external collaboration and coordination with the Association of Food and Drug Officials (AFDO), the National Association of State Departments of Agriculture (NASDA), and state produce regulatory programs. FDA, NASDA, AFDO, and states worked collaboratively to develop the content of the PRPS. A copy of the standards and accompanying worksheets and forms is available in the Federal Register docket for this notice. We recommend that State and Territorial produce safety regulatory programs use these program standards as the framework to design and manage their produce safety regulatory programs. The states that assisted in the development of PRPS were representative of the 43 State and Territorial programs regulatory programs enrolled currently conducting produce safety inspections via funding from a cooperative agreement grant, "The FDA's Cooperative Agreement

Program for States and Territories to Implement a National Produce Safety Program, PAR–21–174," (this program also includes 4 programs which do not conduct inspections). For more information on this cooperative agreement, we invite you to visit our website at: https://www.fda.gov/federal-state-local-tribal-and-territorial-officials/grants-and-cooperative-agreements/fda-state-produce-safety-implementation-cooperative-agreement-program.

The PRPS identifies and includes resource and training material for the following standards: regulatory foundations; training; inspection; product-specific illnesses, outbreaks and hazard response; compliance and enforcement; industry and community relations; program assessments; and product sampling and testing. We recommend using the worksheets and forms contained in the standards. however, alternate forms that are equivalent may be used. The educational worksheets and resource materials include recordkeeping and reporting activities that help FDA verify participation and successful completion of the respective requirements. In the first year of enrollment, information is used to conduct a baseline self-assessment to determine whether the materials meet the elements of each standard. In subsequent years, we use the information to conduct a comprehensive review and evaluate program effectiveness and participation. We modify the program standards based on the ongoing assessments as well as comments and informal feedback obtained from participants.

Description of Respondents: Respondents are State Departments of Agriculture or Health regulatory officials who enroll in the PRPS (State or Territorial governments). Currently we estimate 43 respondents to the information collection based on expected participation.

In the **Federal Register** of June 28, 2024 (89 FR 54009), FDA published a 60-day notice requesting public comment on the proposed collection of information. One comment was received that did not pertain to the information collection.

FDA estimates the burden of this collection of information as follows:

TABLE 1—ESTIMATED ANNUAL RECORDKEEPING BURDEN 1

Respondent	Number of recordkeepers	Number of records per recordkeeper	Total annual records	Average burden per recordkeeping	Total hours
State or Territorial Governments; Maintenance of data records consistent with the PRPS	48	11	528	85.36	45,072

¹There are no capital costs or operating and maintenance costs associated with this collection of information.

Dated: October 30, 2024.

Kimberlee Trzeciak,

Deputy Commissioner for Policy, Legislation, and International Affairs.

[FR Doc. 2024–26209 Filed 11–12–24; 8:45 am] BILLING CODE 4164–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Health Resources and Services Administration

Charter Renewal for the Advisory Committee on Heritable Disorders in Newborns and Children

AGENCY: Health Resources and Services Administration (HRSA), Department of Health and Human Services.

ACTION: Notice.

SUMMARY: In accordance with the Federal Advisory Committee Act, the Department of Health and Human Services is hereby giving notice that the Advisory Committee on Heritable

Disorders in Newborns and Children (ACHDNC) charter has been renewed.

DATES: The effective date of charter renewal is November 10, 2024.

FOR FURTHER INFORMATION CONTACT:

Leticia Manning, Maternal and Child Health Bureau, HRSA, 5600 Fishers Lane, 18N38A, Rockville, Maryland 20857; 301–443–8335; or *lmanning@hrsa.gov*.

SUPPLEMENTARY INFORMATION: ACHDNC provides advice and recommendations to the Secretary of Health and Human Services (Secretary) on the development of newborn screening activities, technologies, policies, guidelines, and programs for effectively reducing morbidity and mortality in newborns and children having, or at risk for, heritable disorders. ACHDNC reviews and reports regularly on newborn and childhood screening practices, recommends improvements in the national newborn and childhood screening programs, and fulfills requirements stated in the authorizing

legislation. In addition, ACHDNC's recommendations regarding inclusion of conditions for screening on the Recommended Uniform Screening Panel, following adoption by the Secretary, are evidence-informed preventive health services provided for in the comprehensive guidelines supported by HRSA pursuant to section 2713 of the Public Health Service Act (42 U.S.C. 300gg-13). Under this provision, non-grandfathered group health plans and health insurance issuers offering non-grandfathered group or individual health insurance are required to provide insurance coverage without cost-sharing (a co-payment, coinsurance, or deductible) for preventive services for plan years (i.e., policy years) beginning on or after the date that is 1 year from the Secretary's adoption of the condition for screening.

The charter renewal for the ACHDNC was approved on October 29, 2024. The filing date is November 10, 2024. Renewal of the ACHDNC charter

authorizes the committee to operate until November 10, 2026

A copy of the ACHDNC charter is available on the ACHDNC website at https://www.hrsa.gov/advisory-committees/heritable-disorders/index.html. A copy of the charter also can be obtained by accessing the FACA database that is maintained by the Committee Management Secretariat under the General Services Administration. The website address for the FACA database is http://www.facadatabase.gov/.

Maria G. Button,

Director, Executive Secretariat. [FR Doc. 2024–26198 Filed 11–12–24; 8:45 am]

BILLING CODE 4165-15-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Office of the Secretary; Notice of Meeting

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the National Science Advisory Board for Biosecurity.

The meeting will be held as a virtual meeting and will be open to the public as indicated below. Individuals who plan to view the virtual meeting and need special assistance or other reasonable accommodations to view the meeting should notify the Contact Person listed below in advance of the meeting. The meeting will be videocast and can be accessed from the NIH Videocasting and Podcasting website (http://videocast.nih.gov/).

Name of Committee: National Science Advisory Board for Biosecurity. Date: November 21, 2024.

Time: 1:00 p.m. to 2:00 p.m.

Agenda: The National Science Advisory Board for Biosecurity meeting will include a review of a new charge to the committee and discussion of next steps for the committee.

Address: National Institutes of Health, 6705 Rockledge Drive, Suite 630, Bethesda, MD 20892.

Meeting Format: Virtual Meeting. Meeting Access: https://osp.od.nih.gov/ policies/national-science-advisory-board-forbiosecurity-nsabb#tab3/.

Contact Person: Cari Young, ScM, Office of Science Policy, Office of the Director, National Institutes of Health, 6705 Rockledge Drive, Suite 630, Bethesda, MD 20892, 301–496–9838, SciencePolicy@od.nih.gov.

This notice is being published less than 15 days from the meeting date due to exceptional circumstances which did not allow sufficient time to submit the notice within the typical lead time

required for publication. The National Science Advisory Board for Biosecurity meeting will include review of a new charge to the committee that, in keeping with the committee's charter, is of vital importance to biomedical research. public health, and national security. If the meeting is not held on November 21, 2024, committee members and participants with the requisite scientific, technical, public health, biodefense, and national security expertise will be unable to participate due to scheduling conflicts. Information is also available on the Institute's/Center's home page: https://osp.od.nih.gov/policies/nationalscience-advisory-board-for-biosecuritynsabb#tab3/, where an agenda and any additional information for the meeting will be posted when available.

Dated: November 7, 2024.

David W. Freeman.

Supervisory Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2024–26268 Filed 11–12–24; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting

following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Allergy and Infectious Diseases Acquired Immunodeficiency Syndrome Research Committee (AIDS) Special Emphasis Panel.

Date: December 5, 2024.

Time: 1:00 p.m. to 3:00 p.m. Agenda: To review and evaluate grant applications.

Place: National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 3E71, Rockville, MD 20892 (Video Assisted Meeting).

Contact Person: Samita S. Andreansky, Ph.D., Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 3E71, Rockville, MD 20892, 240–669–2915, samita.andreansky@nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS)

Dated: November 6, 2024.

Lauren A. Fleck,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2024–26187 Filed 11–12–24; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Administration for Strategic Preparedness and Response

National Advisory Committee on Children and Disasters Public Meeting

AGENCY: Administration for Strategic Preparedness and Response (ASPR), U.S. Department of Health and Human Services (HHS).

ACTION: Notice.

SUMMARY: The National Advisory
Committee on Children and Disasters
(NACCD or the Committee) will conduct
a public meeting (virtual) to discuss
potential recommendations to the HHS
Secretary and ASPR regarding
challenges, opportunities, and priorities
for national public health and medical
preparedness, response, and recovery
specific to the needs of children and
their families in disasters.

DATES: The public meeting (virtual) will be held December 4, 2024.

ADDRESSES: A more detailed agenda and meeting registration link will be available on the NACCD meeting website at https://aspr.hhs.gov/AboutASPR/WorkingwithASPR/BoardsandCommittees/Pages/NACCD/Public-Meetings.aspx.

FOR FURTHER INFORMATION CONTACT:

Zhoowan Jackson, NACCD Designated Federal Officer, Administration for Strategic Preparedness and Response (ASPR), U.S. Department of Health and Human Services (HHS), Washington, DC; 202–205–4217, NACCD@hhs.gov.

SUPPLEMENTARY INFORMATION: The NACCD is established by section 2811A of the Public Health Service Act (42 U.S.C. 300hh-10b) as amended by the Pandemic and All Hazards Preparedness and Advancing Innovation Act and governed by the provisions of the Federal Advisory Committee Act (5 U.S.C. app.). The statute directs the